Bristol Myers Squibb's second quarter revenue of $13.0B and EPS of $2.04 beat estimates, prompting a raised full-year 2026 outlook.

Bristol Myers Squibb reported second quarter 2026 revenues of $13.0 billion, up 6% year-over-year, and a non-GAAP EPS of $2.04. The results significantly surpassed analyst expectations, leading the company to increase its full-year guidance.

Key Highlights

• The company's Growth Portfolio revenues increased 15% to $7.6 billion, driven by strong performance from products including Reblozyl, Camzyos, and Opdualag.
• Full-year 2026 guidance was raised, with revenue now projected at $49.0-$50.0 billion (from $46.0-$47.5 billion) and non-GAAP EPS at $6.75-$7.00 (from $6.05-$6.35).
• Legacy Portfolio revenues declined 4% to $5.4 billion, largely due to ongoing generic competition for Revlimid, which saw its worldwide sales fall 49% to $425 million.